Vitamin E to Treat Uveitis-Associated Macular Edema

INCLUSION CRITERIA: Patients with documented cystoid macular edema associated with intraocular inflammatory disease. This should be documented both by clinical examination and by fluorescein angiography and should be agreed upon by two independent observers. Patients must have at least one eye with best corrected visual acuity of 20/32 or less (as measured by the ETDRS chart) and macular edema. These will be considered eligible eyes. A patient must have at lease one eligible eye with clinical opacity grades of less than or equal to 1+ for posterior sub-capsular opacity and less than or equal to 2+ for nuclear opacity. Patients 9 years and above, of either sex (non-pregnant females), who carry the diagnosis of endogenous anterior, intermediate, posterior, or panuveitis. Patients may be receiving systemic therapy for the treatment of their cystoid macular edema, or may have been treated for the cystoid macular edema in the past. Vitreous haze in both eyes equal to or less than 1+ cell and 1+ haze. The patient or patient's guardian must understand and sign the protocol informed consent and/or assent document. EXCLUSION CRITERIA: Periocular injection of steroids within the previous month or potential need for injections during the study. Systemic immunomodulatory agent(s) added or increased in dosage (greater than 20%) within the last two months, or potential need for any increase during the study. Patients requiring prednisone greater than 30 mg per day at the time of enrollment. Vitamin E supplementation over and above the amount in a multivitamin (60 IU/day) one month prior to entry into the study. History of hypersensitivity to fluorescein. Unclear media which precludes assessment of cystoid macular edema in eligible eye(s), such as a cataract or vitreal opacity. Evidence of a macular subretinal neovascular net or a macular hole in the eligible eye(s). Prior or current macular detachment in eligible eye(s). Concurrent coumadin (warfarin) therapy or known bleeding diathesis. Concurrent treatment with a new investigational drug. Malabsorption syndrome. Concurrent administration of anti-cholesterol resin medications (e.g. cholestyramine). Concurrent administration of the anti-obesity drug orlistat. Pregnant or lactating women. Medical problems that make consistent follow-up over the treatment period unlikely (e.g. stroke, severe myocardial infarction, terminal carcinoma). Inability to comply with the study requirements. Severe optic nerve atrophy in eligible eye(s). History of intercranial bleeds.